Loading…
Globus Medical, Inc. is projected to rise to $91.77 by 2027, a +11% move from its current price of $82.54. GMED is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $80.84 | $82.54 | $84.28 | 0.00% |
| May 30 | $80.15 | $82.54 | $85.01 | 0.00% |
| May 31 | $79.62 | $82.54 | $85.58 | 0.00% |
| Jun 1 | $79.18 | $82.54 | $86.06 | +0.01% |
| Jun 2 | $78.79 | $82.55 | $86.48 | +0.01% |
| Jun 3 | $78.44 | $82.55 | $86.87 | +0.01% |
| Jun 4 | $78.12 | $82.55 | $87.22 | +0.01% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $78.12 | $82.55 | $87.22 | +0.01% |
| Week 2 | $76.37 | $82.56 | $89.25 | +0.02% |
| Week 3 | $75.05 | $82.56 | $90.83 | +0.03% |
| Week 4 | $73.95 | $82.57 | $92.19 | +0.04% |
| Week 5 | $73.00 | $82.58 | $93.41 | +0.05% |
| Week 6 | $72.16 | $82.59 | $94.52 | +0.06% |
| Week 7 | $71.39 | $82.59 | $95.56 | +0.07% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products comprising traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices; treatment options for motion preservation technologies consisting of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and biologic solutions, such as allografts and synthetic alternatives.
It also provides orthopedic trauma solutions, including limb reconstruction, fracture plating, intramedullary nailing, external fixation, and compression screw technologies; hip and knee arthroplasty solutions, including modular cement and cementless hip stems, acetabular cups, femoral heads, highly cross-linked liners, partial knee systems, cruciate retaining, posterior stabilized, and revision options; spinal cord stimulation services; and neuromonitoring services. In addition, it offers ExcelsiusGPS platform, a robotic guidance and navigation system for minimally invasive and open procedures; Surgimap, a surgical planning software platform; Excelsius3D, a platform combined with ExcelsiusGPS that provides an intraoperative and image-guided robotic navigation solution; ExcelsiusHub, which provides real-time patient array monitoring, tissue sparing drills, and registration flexibility; and ExcelsiusFlex, a total knee arthroplasty robotic solution. Further, it distributes human cells, tissues, and cellular and tissue-based products.
The company sells its products through direct and distributor sales representatives; and independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
Globus Medical, Inc. (GMED) is currently priced at $84.81 per share and has a market capitalization of $11.51B. It is ranked 835 in the market. The current price and market position place it within a landscape where near-term movement is guided by a defined 30-day trading range and a broad set of long-term projections.
The long-range forecast shows substantial upside potential, with average prices rising across multiple future years and terminal upside by 2050.
A major floor 22.8% below — a decisive break under it would weaken the trend.
The nearest floor, 8.4% below — buyers have tended to step in here.
The nearest ceiling, 17.3% above — a clean break opens room to run.
A major ceiling 28.7% above — clearing it would confirm fresh momentum.
Key GMED support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of GMED market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $84.22 | Sell | $83.24 | Sell |
| MA 10 | $80.94 | Buy | $82.68 | Sell |
| MA 20 | $83.22 | Sell | $83.73 | Sell |
| MA 50 | $87.41 | Sell | $86.22 | Sell |
| MA 100 | $88.97 | Sell | $85.86 | Sell |
| MA 200 | $79.43 | Buy | $81.87 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 45.12 | Neutral |
| Stoch RSI (14) | 77.70 | Neutral |
| CCI (20) | -9.54 | Neutral |
| Williams %R (14) | -26.86 | Info |
| MACD (12,26,9) | 0.64 | Buy |
| ROC (12) | 5.89 | Buy |
| Bollinger %B (20,2) | 0.47 | Neutral |
| Stochastic %K (14) | 73.14 | Neutral |
| TRIX (15) | -0.42 | Sell |
| Awesome (5,34) | -3.31 | Sell |
| Ultimate (7,14,28) | 60.26 | Neutral |
| Momentum (10) | 6.41 | Buy |
| Aroon Osc (25) | -60.00 | Sell |
| Hull MA (9) | 85.96 | Sell |
| ADX (14) | 18.62 | Neutral |
| ATR (14) | 1.61 | Info |
Technical sentiment is BULLISH with RSI14 at 50. The stock trades above the longer-term trend and sits near key moving averages: SMA50 at $87.46 and SMA200 at $79.15. Near-term support is identified at $75.57 and resistance at $96.82, providing a defined trading corridor in the current cycle.
Over the last 30 days, the price range was $73.79 to $97.47, illustrating a constructive but bounded movement within that band. Annualized volatility sits around 40%, underscoring meaningful price swings within the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $75.57 | $82.54 | $106.53 | 0% | Neutral | |
| $74.45 | $91.77 | $118.75 | +11% | Neutral | |
| $75.47 | $94.92 | $126.35 | +15% | Neutral | |
| $88.03 | $112.58 | $153.25 | +36% | Bullish | |
| $99.45 | $129.08 | $179.11 | +56% | Bullish | |
| $107.37 | $141.24 | $199.31 | +71% | Bullish | |
| $121.82 | $162.28 | $232.49 | +97% | Bullish | |
| $123.19 | $166.03 | $241.17 | +101% | Bullish | |
| $124.61 | $169.81 | $249.83 | +106% | Bullish | |
| $134.08 | $184.65 | $274.91 | +124% | Bullish | |
| $194.34 | $280.62 | $439.33 | +240% | Bullish | |
| $337.63 | $527.82 | $890.16 | +539% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $75.57 | $82.54 | $96.85 | +0.00% |
| June 2026 | $70.84 | $82.77 | $98.68 | +0.28% |
| July 2026 | $70.28 | $82.64 | $99.56 | -0.15% |
| August 2026 | $71.99 | $85.07 | $103.31 | +2.94% |
| September 2026 | $72.88 | $86.48 | $105.70 | +1.65% |
| October 2026 | $71.38 | $85.02 | $104.53 | -1.69% |
| November 2026 | $70.80 | $84.61 | $104.57 | -0.48% |
| December 2026 | $71.55 | $85.77 | $106.53 | +1.37% |
Click any year to see its month-by-month GMED forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Globus Medical, Inc.'s 2026 outlook centres on $82.54, within a $75.57 to $106.53 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, GMED could reach as high as $118.75, with a base case around $91.77 and support toward $74.45 — roughly +11% from $82.54. A consolidation phase looks the most probable path here.
Expect GMED to range from $75.47 to $126.35 through 2028. The $94.92 average target implies a +15% move from current prices. That is up +3% on the projected 2027 average. Price action looks broadly range-bound.
The GMED price prediction for 2029 points to an average of $112.58 (low $88.03, high $153.25) — a potential gain of +36% on today's $82.54. Buyers look set to stay in control over this stretch.
In 2030, GMED is projected to trade between $99.45 and $179.11, averaging $129.08 — a potential gain of +56% from today's $82.54. That is up +15% on the projected 2029 average. Momentum favours further upside here.
Globus Medical, Inc.'s 2031 outlook centres on $141.24, within a $107.37 to $199.31 range. That is up +9% on the projected 2030 average. That marks a +71% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, GMED could reach as high as $232.49, with a base case around $162.28 and support toward $121.82 — roughly +97% from $82.54. Momentum favours further upside here.
Expect GMED to range from $123.19 to $241.17 through 2033. The $166.03 average target implies a +101% move from current prices. That is up +2% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The GMED price prediction for 2034 points to an average of $169.81 (low $124.61, high $249.83) — a potential gain of +106% on today's $82.54. Momentum favours further upside here.
In 2035, GMED is projected to trade between $134.08 and $274.91, averaging $184.65 — a potential gain of +124% from today's $82.54. That is up +9% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Globus Medical, Inc.'s 2040 outlook centres on $280.62, within a $194.34 to $439.33 range. That is up +52% on the projected 2035 average. That marks a +240% change versus current levels. Momentum favours further upside here.
By 2050, GMED could reach as high as $890.16, with a base case around $527.82 and support toward $337.63 — roughly +539% from $82.54. Buyers look set to stay in control over this stretch.
Investing $1,000 in GMED today (≈ 12.115338 GMED) could be worth
$6,394.72
+$5,394.72 (+539%) by 2050 · US Dollar
Based on the average projected GMED price of $527.82 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in GMEDwould be worth at today's price.
$1,000 invested in GMED on May 27, 2025 (≈ 16.781339 GMED) would be worth
$1,385.13
+$385.13 (+38.5%) today · 1.39× · US Dollar
Based on a GMED entry price of $59.59 vs. today's $82.54.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $84.03 | $982.27 | -1.8% |
| 1 month ago | $93.7 | $880.9 | -11.9% |
| 3 months ago | $96.71 | $853.48 | -14.7% |
| 6 months ago | $91.04 | $906.63 | -9.3% |
| 1 year ago | $59.59 | $1,385.13 | +38.5% |
| All time (5.0y) ago | $72.11 | $1,144.64 | +14.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our GMED forecast.
Our base-case forecast reaches $170.00 around 2035.
Implied market cap at $170.00: $19.26B
The year-by-year forecast shows a gradual but persistent appreciation in value across the horizon. The 2026 average price is $84.81 with a min of $75.57 and a max of $110.49, yielding an initial neutral stance. From 2027 onward, the average price climbs to $95.82 (2027), $101.12 (2028), $121.12 (2029), and $139.69 (2030), with corresponding ROI of 13%, 19.2%, 42.8%, and 64.7%.
The upward trajectory continues through 2031–2035 with averages of $154.18, $177.89, $182.02, $187.87, and $205.98, and ROI rising to 81.8%, 109.8%, 114.6%, 121.5%, and 142.9% respectively. In 2040 the forecast shows an average of $318.78 with ROI 275.9%, and by 2050 the average reaches $611.16 with a max of $1,035.17 and ROI 620.6%. The sentiment remains BULLISH from 2029 onward, reflecting a clear long-term upside potential, but these are estimates and not guarantees.
The model also notes substantial near-term volatility, given an annualized volatility of 40%.
Tap a question to reveal the answer.
Avg: $139.69; min: $107.41; max: $194.31; ROI: 64.7%. Sentiment: BULLISH.
The forecast shows rising average prices and positive ROI in multiple years, including 2029 (avg $121.12, ROI 42.8%), 2030 (avg $139.69, ROI 64.7%), and 2050 (avg $611.16, ROI 620.6%). These are estimates, not guarantees.
Yes. The 2026 max forecast is $110.49, and later years show higher highs (e.g., 2030 max $194.31). A $100 level is projected to be surpassed within the forecast horizons.
$84.81 per share.
Low: $73.79, High: $97.47.
Globus Medical, Inc. Community Discussion
0Share your Globus Medical, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.